In January 2018, the panCanadian Pharmaceutical (pCPA) announced that price negotiations for Kyprolis® (carfilzomib) for two indications to treat myeloma are now complete. A completed panCanadian negotiation refers to those for which a Letter of Intent* (LOI) has been signed between the lead jurisdiction for the negotiation and the manufacturer (in this case Amgen) or negotiations have been closed without a Letter of Intent.